Incannex Healthcare Completes Database Lock For RePOSA Phase 2 Clinical Trial Of IHL-42X, Drug Candidate For Obstructive Sleep Apnoea

Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, is pleased to announce that it has achieved database lock for the RePOSA Phase 2 clinical trial of IHL-42X, its lead drug candidate for obstructive sleep apnoea (OSA), on schedule as of 16 June 2025.

This marks a major milestone in the development of IHL-42X, confirming the completion of clinical data collection and enabling final statistical analysis to begin. The Company is on track to deliver top-line results in July 2025, reinforcing confidence in the program's momentum and execution.

The RePOSA Phase 2 trial is evaluating IHL-42X in patients with moderate to severe OSA who are unable or unwilling to use continuous positive airway pressure (CPAP). The proprietary fixed-dose combination therapy is designed to reduce apnoea episodes, improve sleep quality, and offer a patient-friendly alternative to current treatment options.

With over 900 million people affected by OSA worldwide and growing awareness of its impact on cardiovascular and metabolic health, IHL-42X is positioned to disrupt the treatment paradigm and deliver meaningful clinical benefit to a vastly underserved patient population.

This achievement builds on positive results from earlier studies and marks the next step in the Company's strategy to commercialise IHL-42X as a first-in-class, market-leading therapeutic solution for OSA.